Fluxus Technologies

Fluxus is a biotechnology and medical device company specializing in optofluidics and single-molecule counting technologies. Founded in 2016 and based in Sunnyvale, California, the company develops and manufactures biochip-based detection platforms for ultrasensitive diagnostic and bioanalytical applications. Its technology integrates advanced photonics, microfluidics, and assay development to enable precise detection and monitoring of biomarkers. By combining these engineering and scientific disciplines, the company creates systems designed to provide high-sensitivity performance for diverse clinical and research needs.

The company focuses on addressing critical gaps in clinical research and diagnostics, aiming to advance the detection, treatment, and monitoring of diseases. Its solutions are designed for use by clinicians, researchers, and industry partners to improve diagnostic yields. Since its 2022 acquisition, Fluxus has operated as a subsidiary of Fujirebio Holdings, Inc., blending the agility of a startup with the resources of an established multinational organization. Its technology has been applied in the development of assays for various pathogens and conditions, supporting efforts to deliver accurate, high-performance testing tools to healthcare environments.